USPTO serial 87824804
MULTICROSS
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- DICKSON, RACHAEL
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with MULTICROSS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sara Citrowske
Sara Citrowske Boston Scientific CorporationOne Scimed PlaceMaple Grove, MN 55311UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 010 | Surgical and medical apparatus, instruments and devices for use in the prevention and treatment of circulatory system issues and conditions; surgical and medical apparatus, instruments and devices for use in the prevention and treatment of pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusions, blood clots, vascular issues and conditions, intracranial haemorrhages, cerebral haemorrhages, hematomas, peripheral vascular lesions, and coronary vascular lesions; medical and surgical catheters for use in the prevention and treatment of circulatory system issues and conditions; medical and surgical catheters for use in the prevention and treatment of pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusions, blood clots, vascular issues and conditions, intracranial haemorrhages, cerebral haemorrhages, hematomas, peripheral vascular lesions, and coronary vascular lesions; catheters and microcatheters; parts and fittings for all the aforesaid goods | ACTIVE | — |
| 041 | Education services, namely, developing, arranging and conducting educational programmes and providing courses of instruction in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine and in the fields of the prevention and treatment of circulatory system issues and conditions, namely, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, intracranial haemorrhages, cerebral haemorrhages, hematomas, peripheral vascular lesions, and coronary vascular lesions, and distribution of course material in connection therewith; training in the use and operation of medical devices and medical research apparatus and consultation relating thereto; educational services, namely, conducting live and online seminars, classes, workshops, lectures, panel discussions, and training programs in the fields of health care and medical diseases, disorders and related treatments and in the fields of the prevention and treatment of circulatory system issues and conditions, namely, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, intracranial haemorrhages, cerebral haemorrhages, hematomas, peripheral vascular lesions, and coronary vascular lesions, and distribution of course material in connection therewith; educational services, namely, providing non-downloadable webinars in the fields of health care and medical diseases, disorders and related treatments in relation to the prevention and treatment of circulatory system issues and conditions, namely, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, intracranial haemorrhages, cerebral haemorrhages, hematomas, peripheral vascular lesions, and coronary vascular lesions, and distribution of course material in connection therewith; provision of educational content, namely, providing on-line instruction in the fields of health care and medical diseases, disorders and related treatments in relation to the prevention and treatment of circulatory system issues and conditions, namely, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, intracranial haemorrhages, cerebral haemorrhages, hematomas, peripheral vascular lesions, and coronary vascular lesions, and distribution of course material in connection therewith; providing online computer and electronic databases featuring information about medical education in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; advisory services in the field of medical education; educational services, namely, conducting live and online seminars, classes, workshops, lectures, panel discussions and training in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine; educational services, namely, providing non-downloadable webinars in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and distribution of course material in connection therewith; non-downloadable electronic publications in the nature of teaching guides, instructional materials, brochures, and course books in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine and in relation to the prevention and treatment of circulatory system issues and conditions, namely, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, intracranial haemorrhages, cerebral haemorrhages, hematomas, peripheral vascular lesions, and coronary vascular lesions; electronic online databases featuring information about medical education in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Roxwood Medical, Inc.
- Other trademarks owned by Roxwood Medical, Inc.
- Other trademarks in Class 010
- Other trademarks in Class 041
- Similar marks named MULTICROSS
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 27, 2021 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 27, 2021 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 13, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 12, 2021 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Feb 10, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 28, 2021 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jan 28, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 30, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 30, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 30, 2020 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Aug 30, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 30, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 30, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 27, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 25, 2020 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Aug 25, 2020 | EXT3 | SOU EXTENSION 3 FILED | — |
| Aug 25, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 27, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 25, 2020 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 25, 2020 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 25, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 21, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 19, 2019 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 19, 2019 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 19, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 26, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 1, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 1, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 12, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 29, 2018 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Nov 29, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 27, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 27, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 27, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 27, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 21, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 21, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 21, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 19, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 29, 2018 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Mar 29, 2018 | ALIE | ASSIGNED TO LIE | — |
| Mar 23, 2018 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 23, 2018 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 14, 2018 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Mar 14, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 10, 2018 | NWAP | NEW APPLICATION ENTERED | — |